HK1199494A1 - Characterization of cho-mif gene and protein, and use thereof cho-mif - Google Patents

Characterization of cho-mif gene and protein, and use thereof cho-mif

Info

Publication number
HK1199494A1
HK1199494A1 HK14113002.3A HK14113002A HK1199494A1 HK 1199494 A1 HK1199494 A1 HK 1199494A1 HK 14113002 A HK14113002 A HK 14113002A HK 1199494 A1 HK1199494 A1 HK 1199494A1
Authority
HK
Hong Kong
Prior art keywords
cho
mif
characterization
protein
gene
Prior art date
Application number
HK14113002.3A
Other languages
English (en)
Chinese (zh)
Inventor
Randolf J Kerschbaumer
Dirk Voelkel
Gerhard Antoine
Fritz Scheiflinger
C Geert Mudde
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of HK1199494A1 publication Critical patent/HK1199494A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/03—Intramolecular oxidoreductases (5.3) transposing C=C bonds (5.3.3)
    • C12Y503/03012—L-Dopachrome isomerase (5.3.3.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14113002.3A 2011-10-07 2014-12-27 Characterization of cho-mif gene and protein, and use thereof cho-mif HK1199494A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161545047P 2011-10-07 2011-10-07
PCT/EP2012/069602 WO2013050457A1 (fr) 2011-10-07 2012-10-04 Caractérisation du gène et de la protéine cho-mif, et son utilisation

Publications (1)

Publication Number Publication Date
HK1199494A1 true HK1199494A1 (en) 2015-07-03

Family

ID=47010580

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14113002.3A HK1199494A1 (en) 2011-10-07 2014-12-27 Characterization of cho-mif gene and protein, and use thereof cho-mif

Country Status (8)

Country Link
US (2) US9465037B2 (fr)
EP (1) EP2753937B1 (fr)
JP (1) JP2014530361A (fr)
AR (1) AR088245A1 (fr)
AU (1) AU2012327159B2 (fr)
HK (1) HK1199494A1 (fr)
TW (2) TW201639957A (fr)
WO (1) WO2013050457A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050453A1 (fr) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif en tant que marqueur de diagnostic
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
JP2015523572A (ja) * 2012-07-10 2015-08-13 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 抗ｍｉｆ免疫組織化学法
US10626166B2 (en) * 2014-08-22 2020-04-21 Baxalta Incorporated Detection of CHO-MIF contaminations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
DE69435303D1 (de) * 1993-05-17 2010-09-02 Cytokine Pharmasciences Inc Er behandlung von krankheiten bei denen eine cytok
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
WO2009008690A2 (fr) * 2007-07-06 2009-01-15 Oleg Badyrov Réservoir de rinçage de wc
DK2231707T3 (en) * 2008-01-04 2015-03-02 Baxter Int Anti-mif antibodies

Also Published As

Publication number Publication date
TW201319571A (zh) 2013-05-16
EP2753937A1 (fr) 2014-07-16
AR088245A1 (es) 2014-05-21
TW201639957A (zh) 2016-11-16
US20170210794A1 (en) 2017-07-27
TWI569013B (zh) 2017-02-01
JP2014530361A (ja) 2014-11-17
US20140287443A1 (en) 2014-09-25
US9465037B2 (en) 2016-10-11
WO2013050457A1 (fr) 2013-04-11
EP2753937B1 (fr) 2018-01-17
AU2012327159A1 (en) 2013-05-16
AU2012327159B2 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
IL260045B (en) Polypeptide structures and their uses
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
EP2721063A4 (fr) Polypeptides liant pcsk9 et leurs procédés d'utilisation
EP2791333A4 (fr) Polypeptides opsines et leurs procédés d'utilisation
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
EP2670866A4 (fr) Biomarqueurs et leurs procédés d'utilisation
WO2014055790A9 (fr) Procédés et processus d'évaluation non invasive de variations génétiques
EP2773651A4 (fr) Compositions spécifiques de b7-h4 isolé et procédés d'utilisation associés
IL232977A0 (en) Intra-episode dexmedetomidine preparations and methods of using them
ZA201400561B (en) Axmi279 pesticidal gene and methods for its use
ZA201400563B (en) Axmi270 toxin gene and methods for its use
EP2782589A4 (fr) Peptides antimicrobiens et procédés d'utilisation de ces derniers
EP2833889A4 (fr) Inhibiteurs de protéine kinase c et utilisations de ceux-ci
ZA201400562B (en) Axmi205 variant proteins and methods for their use
EP2738255A4 (fr) Peptide issu de erap1 et son utilisation
ZA201308268B (en) Herbicidal composition comprising pinoxaden and fluroxypyrester, and methods of use thereof
ZA201307363B (en) Axmi115 variant insecticidal gene and methods for its use
EP2818547A4 (fr) Nouveau gène de glycosyltransférase et son utilisation
EP2688901A4 (fr) Inhibiteurs de 17ss-hsd1, 17ss-hsd3 et 17ss-hsd10
EP2664671A4 (fr) Nouveau gène de glycosyltransférase et utilisation de celui-ci
HK1199494A1 (en) Characterization of cho-mif gene and protein, and use thereof cho-mif
IL227816A0 (en) Peptide library, constructs containing them and their uses
ZA201306420B (en) Regulated gene expression systems and constructs thereof
EP2702999A4 (fr) Acide nucléique fonctionnel ciblant le cerveau et son utilisation
GB201117424D0 (en) Characterization of CHO-MIF gene and protein and use thereof